Reports

Browse current and previous editions of Switzer Report

Thursday Edition, 18 September 2025
Maureen Jordan

“HOT” stock: Elders (ELD)

Maureen Jordan · September 18, 2025

The stock is looking attractive here as Elders rolls out new systems to improve its pricing power and margins, and seasonal conditions remain favourable.

Investing Premium
Paul Rickard

Questions of the Week

Paul Rickard · September 18, 2025

Is the Van Eck Bitcoin ETF VBTC a safe and easy way to get exposure to bitcoin? What is going on with lithium producer Sayona Mining? Brambles has softened recently, have there been any broker downgrades? Why is CBA “neutralising” its dividend?

Q&A Premium
Monday Edition, 15 September 2025
James Dunn

Three promising medical device makers

James Dunn · September 15, 2025

The human healthcare industry can be a frustrating place to invest but here are three examples on the ASX that are making a good fist of establishing their respective devices in world markets.

Investing Premium
Switzer on Saturday, 13 September 2025
Peter Switzer

Dud data drops not a negative for stocks

Peter Switzer · September 13, 2025

Disappointing US economic data has underlined the nature of American investors and their commitment to being long stocks, with stocks now on a drive higher on the basis that a rate cut comes next week. It could even be a “jumbo” 50-basis points reduction!

Switzer on Saturday Premium
Thursday Edition, 11 September 2025
Paul Rickard

Questions of the Week

Paul Rickard · September 11, 2025

Should I be worried about a rising Aussie dollar when it comes to my overseas share investments? Lonsec cut its ratings for private credit funds managed by Metric Credit Partners. Should I still invest in the Metrics Master Income Trust (MXT) unit purchase plan? Are the major brokers bullish on MediBank Private? When does CSL pay its next dividend?

Q&A Premium
Monday Edition, 8 September 2025
Paul Rickard

Is Wesfarmers too expensive?

Paul Rickard · September 8, 2025

Wesfarmers (WES) has climbed all year, trading as high as $95.17 before the release of its full year result. Now the question is: Is it too expensive and a sell? Here’s what I think.

Investing Premium
1 23 24 25 26 27 119

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.